Cetuximab for Squamous Cell Carcinoma of the Head and Neck

Author Information
Article Notes and Dates
To Cite : Larizadeh M H. Cetuximab for Squamous Cell Carcinoma of the Head and Neck, Int J Cancer Manag. 2017 ;10(11):e10502. doi: 10.5812/ijcm.10502.
Copyright: Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. .
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Acknowledgements
Footnotes
References
  • 1. Shabani M, Larizadeh MH. A review of chemotherapy for locally advanced head and neck cancers. Rep Radiother Oncol. 2015;2(1):35-42. doi: 10.5812/rro.2(1)2015.2261.
  • 2. Larizadeh MH, Shabani M. Survival following non surgical treatments for oral cancer: a single institutional result. Asian Pac J Cancer Prev. 2012;13(8):4133-6. doi: 10.7314/APJCP.2012.13.8.4133. [PubMed: 23098530].
  • 3. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, et al. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004;31(6):778-85. doi: 10.1053/j.seminoncol.2004.09.007. [PubMed: 15599855].
  • 4. Larizadeh MH, Damghani MA. Sequential chemoradiotherapy in advanced laryngeal cancer: an institutional experience. Asia Pac J Clin Oncol. 2010;6(2):106-10. doi: 10.1111/j.1743-7563.2010.01289.x. [PubMed: 20565422].
  • 5. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med Oncol. 2012;29(4):2481-91. doi: 10.1007/s12032-012-0159-2. [PubMed: 22252310].
  • 6. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010;32(10):1412-21. doi: 10.1002/hed.21365. [PubMed: 20848399].
  • 7. Mehra R, Cohen RB, Burtness BA. The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2008;6(10):742-50. [PubMed: 18997665].
  • 8. Numico G, Franco P, Cristofano A, Migliaccio F, Spinazze S, Silvestris N, et al. Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence. Crit Rev Oncol Hematol. 2013;85(2):112-20. doi: 10.1016/j.critrevonc.2012.05.005. [PubMed: 22743346].
  • 9. Sacco AG, Worden FP. Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors. Onco Targets Ther. 2016;9:1927-43. doi: 10.2147/OTT.S93720. [PubMed: 27110122].
  • 10. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8. doi: 10.1016/S1470-2045(09)70311-0. [PubMed: 19897418].
  • 11. Magrini SM, Buglione M, Corvo R, Pirtoli L, Paiar F, Ponticelli P, et al. Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy for Locally Advanced Head and Neck Cancer: A Randomized Phase II Trial. J Clin Oncol. 2016;34(5):427-35. doi: 10.1200/JCO.2015.63.1671. [PubMed: 26644536].
  • 12. Koutcher L, Sherman E, Fury M, Wolden S, Zhang Z, Mo Q, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):915-22. doi: 10.1016/j.ijrobp.2010.07.008. [PubMed: 20947269].
  • 13. Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, et al. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015;51(7):704-8. doi: 10.1016/j.oraloncology.2015.04.012. [PubMed: 25936651].
  • 14. Riaz N, Sherman E, Koutcher L, Shapiro L, Katabi N, Zhang Z, et al. Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. Am J Clin Oncol. 2016;39(1):27-31. doi: 10.1097/COC.0000000000000006. [PubMed: 24401670].
  • 15. Levy A, Blanchard P, Bellefqih S, Brahimi N, Guigay J, Janot F, et al. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas. Strahlenther Onkol. 2014;190(9):823-31.
  • 16. Ley J, Mehan P, Wildes TM, Thorstad W, Gay HA, Michel L, et al. Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology. 2013;85(5):290-6. doi: 10.1159/000355194. [PubMed: 24217231].
  • 17. Tang C, Chan C, Jiang W, Murphy JD, von Eyben R, Colevas AD, et al. Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer. Head Neck. 2015;37(3):386-92. doi: 10.1002/hed.23609. [PubMed: 24431011].
  • 18. Shapiro LQ, Sherman EJ, Riaz N, Setton J, Koutcher L, Zhang Z, et al. Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). Oral Oncol. 2014;50(10):947-55. doi: 10.1016/j.oraloncology.2014.07.001. [PubMed: 25132089].
  • 19. Huang J, Baschnagel AM, Chen P, Gustafson G, Jaiyesmi I, Folbe M, et al. A matched-pair comparison of intensity-modulated radiation therapy with cetuximab versus intensity-modulated radiation therapy with platinum-based chemotherapy for locally advanced head neck cancer. Int J Clin Oncol. 2014;19(2):240-6. doi: 10.1007/s10147-013-0540-y. [PubMed: 23479120].
  • 20. Petrelli F, Coinu A, Riboldi V, Borgonovo K, Ghilardi M, Cabiddu M, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. Oral Oncol. 2014;50(11):1041-8. doi: 10.1016/j.oraloncology.2014.08.005. [PubMed: 25176576].
  • 21. Egloff AM, Lee JW, Langer CJ, Quon H, Vaezi A, Grandis JR, et al. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Clin Cancer Res. 2014;20(19):5041-51. doi: 10.1158/1078-0432.CCR-14-0051. [PubMed: 25107914].
  • 22. Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol. 2006;24(7):1072-8. doi: 10.1200/JCO.2004.00.1792. [PubMed: 16505426].
  • 23. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32(27):2940-50. doi: 10.1200/JCO.2013.53.5633. [PubMed: 25154822].
  • 24. Kies MS, Holsinger FC, Lee JJ, William WJ, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28(1):8-14. doi: 10.1200/JCO.2009.23.0425. [PubMed: 19917840].
  • 25. Mesia R, Vazquez S, Grau JJ, Garcia-Saenz JA, Lozano A, Garcia C, et al. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2016;94(2):289-96. doi: 10.1016/j.ijrobp.2015.10.019. [PubMed: 26675064].
  • 26. Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, et al. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Ann Oncol. 2014;25(10):2036-41. doi: 10.1093/annonc/mdu248. [PubMed: 25009013].
  • 27. Argiris A, Heron DE, Smith RP, Kim S, Gibson MK, Lai SY, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010;28(36):5294-300. doi: 10.1200/JCO.2010.30.6423. [PubMed: 21079141].
  • 28. Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sire C, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol. 2013;31(7):853-9. doi: 10.1200/JCO.2012.42.3988. [PubMed: 23341517].
  • 29. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-7. doi: 10.1200/JCO.2006.06.7447. [PubMed: 17538161].
  • 30. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568-77. doi: 10.1200/JCO.2005.07.119. [PubMed: 16009950].
  • 31. Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578-87. doi: 10.1200/JCO.2005.07.120. [PubMed: 16009949].
  • 32. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology G. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(34):8646-54. doi: 10.1200/JCO.2005.02.4646. [PubMed: 16314626].
  • 33. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27. doi: 10.1056/NEJMoa0802656. [PubMed: 18784101].
  • 34. Thomson DJ, Ho KF, Ashcroft L, Denton K, Betts G, Mais KL, et al. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Acta Oncol. 2015;54(1):88-98. doi: 10.3109/0284186X.2014.958528. [PubMed: 25279959].
  • 35. Saigal K, Santos ES, Tolba K, Kwon D, Elsayyad N, Abramowitz MC, et al. Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma. Front Oncol. 2014;4:165. doi: 10.3389/fonc.2014.00165. [PubMed: 25072020].
  • 36. Caudell JJ, Sawrie SM, Spencer SA, Desmond RA, Carroll WR, Peters GE, et al. Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatment. Int J Radiat Oncol Biol Phys. 2008;71(3):676-81. doi: 10.1016/j.ijrobp.2007.10.040. [PubMed: 18355979].
  • 37. Echarri MJ, Lopez-Martin A, Hitt R. Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). Cancers (Basel). 2016;8(3). doi: 10.3390/cancers8030027. [PubMed: 26927178].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By: